Sato Yoji, Nakamura Ryo, Satoh Mitsutoshi, Fujishita Kayoko, Mori Satoko, Ishida Seiichi, Yamaguchi Teruhide, Inoue Kazuhide, Nagao Taku, Ohno Yasuo
Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo 158-8501, Japan.
Circ Res. 2005 Sep 16;97(6):550-7. doi: 10.1161/01.RES.0000181431.04290.bd. Epub 2005 Aug 11.
Thyroid hormones have marked cardiovascular effects in vivo. However, their direct effects on vascular smooth muscle cells have been unclear. Because thyroid hormones play critical roles in bone remodeling, we hypothesized that they are also associated with vascular smooth muscle calcification, one of the pathological features of vascular sclerosis. To test this hypothesis, we examined the effects of 3',3,5-triiodo-L-thyronine (T3) on the expression of calcification-associated genes in rat aortic smooth muscle cells (RAOSMCs). Quantitative RT-PCRs revealed that a physiological concentration of T3 (15 pmol/L free T3) increased mRNA level of matrix Gla protein (MGP), which acts as a potent inhibitor of vascular calcification in vivo, by 3-fold in RAOSMCs, as well as in cultured human coronary artery smooth muscle cells. In RAOSMCs transiently transfected with a luciferase reporter gene driven by the MGP promoter, T3 significantly stimulated luciferase activity. In addition, RNA interference against thyroid hormone receptor-alpha gene diminished the effect of T3 on MGP expression. Aortic smooth muscle tissues from methimazole-induced hypothyroid rats (400 mg/L drinking water; 4 weeks) also showed a 68% decrease in the MGP mRNA level, as well as a 33% increase in calcium content compared with that from the control euthyroid animals, whereas hyperthyroidism (0.2 mg T3/kg IP; 10 days) upregulated MGP mRNA by 4.5-fold and reduced calcium content by 11%. Our findings suggest that a physiological concentration of thyroid hormone directly facilitates MGP gene expression in smooth muscle cells via thyroid hormone nuclear receptors, leading to prevention of vascular calcification in vivo.
甲状腺激素在体内对心血管有显著影响。然而,它们对血管平滑肌细胞的直接作用尚不清楚。由于甲状腺激素在骨重塑中起关键作用,我们推测它们也与血管平滑肌钙化有关,血管平滑肌钙化是血管硬化的病理特征之一。为了验证这一假设,我们研究了3',3,5-三碘-L-甲状腺原氨酸(T3)对大鼠主动脉平滑肌细胞(RAOSMCs)中钙化相关基因表达的影响。定量逆转录-聚合酶链反应显示,生理浓度的T3(15 pmol/L游离T3)可使基质Gla蛋白(MGP)的mRNA水平增加3倍,MGP在体内是一种有效的血管钙化抑制剂,在RAOSMCs以及培养的人冠状动脉平滑肌细胞中均如此。在瞬时转染了由MGP启动子驱动的荧光素酶报告基因的RAOSMCs中,T3显著刺激了荧光素酶活性。此外,针对甲状腺激素受体α基因的RNA干扰减弱了T3对MGP表达的影响。与正常甲状腺对照动物相比,用甲巯咪唑诱导的甲状腺功能减退大鼠(400 mg/L饮用水;4周)的主动脉平滑肌组织中MGP mRNA水平也降低了68%,钙含量增加了33%,而甲状腺功能亢进(0.2 mg T3/kg腹腔注射;10天)使MGP mRNA上调了4.5倍,钙含量降低了11%。我们的研究结果表明,生理浓度的甲状腺激素通过甲状腺激素核受体直接促进平滑肌细胞中MGP基因的表达,从而在体内预防血管钙化。